22934-58-3

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-METHOXY-4,5-METHYLENEDIOXYBENZOATE is used as an active pharmaceutical ingredient for its potential therapeutic properties. Its chemical structure allows it to interact with biological targets, making it a candidate for the development of new drugs.
Used in Chemical Synthesis:
In the chemical industry, METHYL 3-METHOXY-4,5-METHYLENEDIOXYBENZOATE serves as an intermediate or a building block in the synthesis of more complex molecules. Its versatile structure can be further modified to create a wide range of compounds with different applications.
Used in Flavor and Fragrance Industry:
METHYL 3-METHOXY-4,5-METHYLENEDIOXYBENZOATE is used as a flavoring agent or a fragrance component due to its aromatic properties. Its unique scent profile can be utilized to create new and innovative fragrances or enhance existing ones.
Used in Material Science:
In the field of material science, METHYL 3-METHOXY-4,5-METHYLENEDIOXYBENZOATE can be incorporated into the development of new materials with specific properties. Its chemical structure may contribute to the creation of materials with improved thermal, mechanical, or electrical characteristics.

Upstream product

• 186581-53-3 diazomethane 
• 526-34-1 5-methoxy-3,4-methylenedioxybenzoic acid 
• 67-56-1 methanol 
• 3934-86-9 methyl 3,4-dihydroxy-5-methoxybenzoate 
• 74-95-3 1,1-dibromomethane 
• 75-11-6 diiodomethane 
• 75-09-2 dichloromethane 
• 149-91-7 3,4,5-trihydroxybenzoic acid 
• 3934-84-7 3,4-dihydroxy-5-methoxybenzoic acid 
• 73340-44-0 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone 
• 74-97-5 chlorobromomethane 
• 77-78-1 dimethyl sulfate 
• 116119-01-8 methyl 7-hydroxybenzo[d][1,3]dioxole-5-carboxylate 
• 142531-43-9 methyl 7-(benzyloxy)benzo[d][1,3]dioxole-5-carboxylate 

Downstream Products

• 22934-59-4 (7-methoxybenzo[d][1,3]dioxol-5-yl)methanol 
• 81474-46-6 4-bromo-7-methoxybenzo[1,3]dioxole-5-carboxylic acid methyl ester 
• 111897-19-9 DDB 
• 5780-07-4 3-methoxy-4,5-methylenedioxybenzaldehyde 
• 96909-07-8 3-(7-Methoxy-benzo[1,3]dioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid methyl ester 
• 96909-18-1 (+/-)-Demethoxymegaphyllone acetate 
• 526-34-1 5-methoxy-3,4-methylenedioxybenzoic acid 
• 1221717-33-4 3-(3-hydroxy-4-methoxyphenyl)-5-(3-methoxy-4,5-methylenedioxyphenyl)-1,2,4-triazole 
• 1257321-38-2 C₁₇H₁₆N₂O₇ 
• 1257321-39-3 C₁₉H₂₀N₂O₈ 
• 1221721-82-9 2-(3-hydroxy-4-methoxyphenyl)-5-(3-methoxy-4,5-methylenedioxyphenyl)-1,3,4-oxadiazole 
• 1221717-58-3 2-(3,4,5-trimethoxyphenyl)-5-(3-methoxy-4,5-methylenedioxyphenyl)-1,3,4-oxadiazole 
• 81474-47-7 methyl-6-bromo-7-methoxybenzo [d] [1, 3] dioxole-5-carboxylate 

Relevant academic research and scientific papers

Design, synthesis and anticancer evaluation of novel 1,3-benzodioxoles and 1,4-benzodioxines

A new set of 1,3-benzodioxoles and 1,4-benzodioxines was designed and synthesized starting from gallic acid as anticancer agents. The antiproliferative effect of the target compounds was evaluated against a panel of cancer cell lines (HepG2, PC-3, MCF-7 and A549) using MTT assay. The 1,4-benzodioxine derivative 11a manifested broad spectrum effect towards the four tested cancer cell lines (IC50 50 = 6.37 μM. Also, flow cytometeric analysis revealed that compound 11a could induce both early and late stage apoptosis in MCF-7 cell line. Moreover, the ability of this compound to stimulate apoptosis in the latter cell line was further confirmed by: increment of Bax/Bcl-2 ratio, increase the expression of tumor suppressor gene p53, boosting the levels of initiator and executioner caspases as well as raise in the amount of cytochrome C. In addition molecular docking study was accomplished on the colchicine binding site of tubulin (pdb: 1SA0) to illustrate the interactions of the most potent compound 11a to the receptor.

Asymmetric total synthesis of four bioactive lignans using donor-acceptor cyclopropanes and bioassay of (?)- and (+)-niranthin against hepatitis B and influenza viruses

The asymmetric total synthesis of four lignans, dimethylmatairesinol, matairesinol, (?)-niranthin, and (+)-niranthin has been achieved using reductive ring-opening of cyclopropanes. Moreover, we performed bioassays of the synthesized (+)- and (?)-niranthins using hepatitis B and influenza viruses, which revealed the relationship between the enantiomeric structure and the anti-viral activity of niranthin.

Design and synthesis of novel parabanic acid derivatives as anticonvulsants

In this work a set of novel derivatives of parabanic acid 9a-d, 12a-d and 13a-d was synthesized and their anticonvulsant potential was evaluated. All the compounds under investigation exhibited anticonvulsant activity in both scPTZ and MES tests. In phase II anticonvulsant study, the trimethoxy phenyl derivative 9a evoked the highest potency among the tested compounds in scPTZ test. It displayed 1.72- and 17.05-folds activity more than the standard drugs phenobarbital and ethosuximide, respectively. In addition, the margin of safety for compound 9a is better than that of the reference antiepileptic drug ethosuximide. Also, compound 9a was devoid of hepatotoxicity indicated by measurements of serum level of ALT, AST, ALP, albumin and total protein. Furthermore, treatment with compound 9a significantly increased the GABA brain level by 2.56-folds compared to the control value. Additionally, molecular docking was performed on the active site of GABA-AT to clarify the interactions of the most potent compound 9a with the enzyme. In MES test, compound 12a exhibited the most potent activity against electric stimuli-induced seizures with the lowest ED50 = 13.7 mg/kg and protective index >36.5. Both candidates 9a and 12a could be a good starting point to develop new molecules as novel antiepileptic drugs.

Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities

Colchicine binding site inhibitors (CBSIs) hold great potential in developing new generations of antimitotic drugs. Unlike existing tubulin inhibitors such as paclitaxel, they are generally much less susceptible to resistance caused by the overexpression

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Cis -restricted 3-aminopyrazole analogues of combretastatins: Synthesis from plant polyalkoxybenzenes and biological evaluation in the cytotoxicity and phenotypic sea urchin embryo assays

We have synthesized a series of novel cis-restricted 4,5-polyalkoxydiaryl- 3-aminopyrazole analogues of combretastatins via short synthetic sequences using building blocks isolated from dill and parsley seed extracts. The resulting compounds were tested in vivo in the phenotypic sea urchin embryo assay to reveal their antimitotic and antitubulin effects. The most potent aminopyrazole, 14a, altered embryonic cell division at 10 nM concentration, exhibiting microtubule-destabilizing properties. Compounds 12a and 14a displayed pronounced cytotoxicity in the NCI60 anticancer drug screen, with the ability to inhibit growth of multi-drug-resistant cancer cells.

Nitrogen-Containing Biphenyl Compounds, Pharmaceutical Compositions of Same, Preparation Methods and Anti-HIV-1 Uses Thereof

Nitrogen-containing biphenyl compounds as represented by formula (I), pharmaceutically acceptable salts or derivatives thereof, pharmaceutical compositions, and preparation methods therefore, and anti-HIV-1 use of the compound. Each substituent group in formula (I) is as defined in the description.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

ANALGESIC THAT BINDS FILAMIN A

A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula A, wherein A, B, X, R1, R2, R7 and R8, and the dashed lines are defined within.